IL6 and achalasia-alacrima syndrome: In addition, a phase IIb trial investigating canakinumab treatment in high-risk diabetic patients demonstrated a significant dose-dependent reduction in various major inflammatory biomarkers (C-reactive protein, IL-6 and fibrinogen).39 These data support the potential of this novel therapeutic option for several inflammatory cardiovascular diseases, including AAAs.